Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.

Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group..

Arthritis Res Ther. 2008;10(5):R109. doi: 10.1186/ar2506. Epub 2008 Sep 11.

2.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group..

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

4.

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.

Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A.

Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189.

5.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

6.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group..

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
7.

Belimumab for the treatment of systemic lupus erythematosus.

Jordan N, D'Cruz DP.

Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29. Review.

PMID:
25543845
8.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group.; BLISS-76 Study Group..

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

9.

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.

Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.

Lupus. 2016 Apr;25(4):346-54. doi: 10.1177/0961203315604909. Epub 2015 Sep 18.

10.

Belimumab: a guide to its use in systemic lupus erythematosus.

Scott LJ, Burness CB, McCormack PL.

BioDrugs. 2012 Jun 1;26(3):195-9. doi: 10.2165/11209060-000000000-00000.

PMID:
22428610
11.

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, Morgan-Cox M, Iikuni N, Silk M, Wallace DJ.

Ann Rheum Dis. 2016 Feb;75(2):323-31. doi: 10.1136/annrheumdis-2015-207653. Epub 2015 Sep 3.

PMID:
26338095
12.

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.

Wiglesworth AK, Ennis KM, Kockler DR.

Ann Pharmacother. 2010 Dec;44(12):1955-61. doi: 10.1345/aph.1P360. Epub 2010 Nov 16. Review.

PMID:
21081710
13.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.

Ann Rheum Dis. 2016 Feb;75(2):332-40. doi: 10.1136/annrheumdis-2015-207654. Epub 2015 Aug 20.

PMID:
26293163
14.

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.

Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P.

J Drug Assess. 2013 Apr 12;2(1):40-8. doi: 10.3109/21556660.2013.792823. eCollection 2013.

15.

Belimumab: review of use in systemic lupus erythematosus.

Boyce EG, Fusco BE.

Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30. Review.

PMID:
22464040
16.

Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.

Espinosa G, Cervera R.

Drugs Today (Barc). 2010 Dec;46(12):891-9. doi: 10.1358/dot.2010.46.12.1544336. Review.

PMID:
21589946
17.

B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.

Harvey PR, Gordon C.

BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.

PMID:
23456653
18.

Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.

Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D, Voelker J, Gomez E, McColm J.

Br J Clin Pharmacol. 2016 May;81(5):908-17. doi: 10.1111/bcp.12860. Epub 2016 Feb 25.

PMID:
26648084
19.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups..

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

20.

Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.

Mosak J, Furie R.

Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575. Review.

PMID:
23553779

Supplemental Content

Support Center